ArticleClinical lymphoma, myeloma & leukemia2026
A Multistakeholder Qualitative Analysis of Barriers to Autologous Stem Cell Transplantation for Multiple Myeloma.
Article in Clinical lymphoma, myeloma & leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeWe investigated autologous stem cell transplantation (ASCT) barriers in a single-center qualitative study by interviewing patients with multiple myeloma (MM), transplant physicians (TPs), and referring physicians (RPs).
methodsPatients with MM and referred for ASCT evaluation between January 01, 2021 and December 31, 2022, TPs from 2 Wisconsin transplant centers, and RPs from rural and urban Wisconsin were recruited. Interviews were conducted using a semi-structured interview guide focused on ASCT barriers. Transcripts were double-coded and reviewed. An initial codebook with prespecified themes based on the interview guide was developed and iteratively revised.
resultsEighteen patients, 5 TPs, and 4 RPs were interviewed. Four major ASCT barriers themes were identified across all stakeholders: caregiver support, patient concerns and knowledge, financial toxicity, and logistics. Unique themes included social support by patients and ASCT referral by physicians. Lacking caregiver support was more common among single, childless, and socially/geographically isolated patients. Patients were most concerned about side effects, long hospital stays, and quality of life. Patients used online websites and support groups to gain knowledge and support. While most patients experienced financial toxicity, care costs were rarely discussed. Distance from transplant center, transportation, and care coordination were barriers. Referrals from community oncologists are a major barrier. Patients never seen at a transplant center may have the most barriers.
conclusionThis qualitative study of both patients and physicians investigating barriers to access to ASCT in MM, provides a much-needed multistakeholder perspective. Interventional strategies targeting key barriers will be critical in improving ASCT utilization in MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.